Vitamin D supplementation potentiate antiviral SOC therapy in chronic HCV patients.

Citation:
Abdel Aziz, A. T., and W. Fathy., "Vitamin D supplementation potentiate antiviral SOC therapy in chronic HCV patients.", The Arab Journal of Laboratory Medicine, vol. 44, issue 3, pp. 683-689, 2019.

Abstract:

Background: HCV is major health problem worldwide, that can lead to hepatic fibrosis, decompensation, and hepatocellular carcinoma. The current standard of care therapy (SOC) for chronic HCV is pegylated interferon/ribavirin (Peg-IFN/ RBV). It has been reported that vitamin D has immune-modulatory effect and alleviates the inflammatory diseases in addition to its role in bone homeostasis. The aim of this study is to evaluate the effect of combined vitamin D supplementation and SOC therapy in chronic HCV patients.
Methods: One hundred chronic HCV patients were classified into two groups (Group 1): 50 patients received the SOC therapy (Group 2): 50 patients received the SOC therapy + vitamin D3. During the treatment course, Vitamin D, liver function were evaluated in 6, 12, 24 and 48 weeks.
Results: vitamin D deficiency was found in both groups at basal time of the study, which then elevated up on treatment. The patients received vitamin D turn HCV RNA negative after 12 weeks of treatment, while those in group1 became negative after 48 weeks. Vitamin D supplementation has positive impact on treatment outcome where sustained viral response (SVR) was achieved in nearly all patients in group 2.
Conclusion: vitamin D accelerate the antiviral treatment effect and has positive impact on sustained viral response.
Key words: vitamin D, HCV, Interferon therapy.

Tourism